Editas medicine stock price.

Sep 30, 2020 · Current Price. $10.65. Price as of November 27, 2023, 4:00 p.m. ET. Both are working on gene-editing therapies, with plenty of potential upside. But which is the better stock right now? You can't ... By contrast, Bluebird and Editas shares both fell by over 50% over the first six months of 2022, while CRISPR's stock price stumbled by a noteworthy 20% during the first half of the year. Image ...Editas Medicine Inc stock price (EDIT) NASDAQ: EDIT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.May-11-23 10:32AM. Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress. (GlobeNewswire) May-10-23 06:02AM. Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 14%. (Simply Wall St.)

Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed.Editas Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. Nov. 03. CI. North American Morning Briefing : S&P 500 Futures -2-. Nov. 03. DJ. Editas Medicine, Inc. to Present Clinical Data from the Rubber and Edithal Trials of Edit-301 At the Ash 2023 Annual Meeting and in A Company-Sponsored ... They need the money for the next leg of the journey, and their stock price is as good as it'll likely get until more data comes out. Take Editas Medicine (EDIT 2.28%) as an example. On June 9, it ...

Price as of December 1, 2023, 4:00 p.m. ET ... Shares of Editas Medicine (EDIT 2.28%) are sliding today, down by 7.2% as of 11:26 a.m. ET. The decline came after the company announced a big shake ...

Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Dec 1, 2023 · According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ... Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 62.28% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Nov 24, 2023 · Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 1. Editas Medicine Editas Medicine is a biotech company that focuses on gene-editing therapies. Like many of its peers in this niche, Editas Medicine currently has no approved products and isn't ...

Insider Monkey’s database tracked Editas Medicine, Inc. (NASDAQ:EDIT) in 8 billionaire portfolios at the end of March. It is one of the top DNA stocks to monitor.

View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.

EDITAS MEDICINE DL-,0001 share price in real-time (A2AC4K / US28106W1036), charts and analyses, news, key data, turnovers, company data.Nov 21, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 51.5% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ... CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …Jun 28, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.

The Editas Medicine stock forecast for tomorrow is $ 10.59, which would represent a 0.59% gain compared to the current price. In the next week, the price of EDIT is expected to decrease by -23.77% and hit $ 8.03. As far as the long-term Editas Medicine stock forecast is concerned, here’s what our predictions are currently suggesting.Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock on the same terms and conditions. All of the shares in the offering ...What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial ...The stock price of Editas Medicine (NASDAQ: EDIT), a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one ...Aug 7, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ... Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...

Robinhood (HOOD 5.91%), in particular, makes this process a breeze with its stock slices option (useful for weighting) and commission-free trading. Put simply, you …Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023.According to 5 analyst offering 12-month price targets in the last 3 months, Editas Medicine has an average price target of $15.4 with a high of $19.00 and a low of $12.00.Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.Mar 10, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ... Current Price. $10.77. Price as of December 1, 2023, 4:00 p.m. ET ... What happened. Shares of Editas Medicine ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics.For Editas Medicine stock forecast for 2031, 12 predictions are offered for each month of 2031 with average Editas Medicine stock forecast of $8.2, a high forecast of $8.21, and a low forecast of $8.19. The average Editas Medicine stock forecast 2031 represents a 4.21% increase from the last price of $7.86999988555908.Oct 15, 2020 · The Editas Medicine stock forecast is 21.770642845038 USD for 2024 November 30, Saturday; and 92.327 USD for 2028 November 30, Thursday with technical analysis. Editas Medicine (EDIT) stock price prediction is 21.770642845038 USD. Get Editas Medicine Inc (EDIT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... Price To Sales (TTM) 26.58. Price To Book ...Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Editas Medicine, Inc. ( EDIT) NASDAQ: EDIT · IEX Real-Time Price · USD Add to Watchlist Buy EDIT 10.58 +0.09 (0.86%) At close: Nov 24, 2023, 1:00 PM 10.53 …

Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.

Get Editas Medicine Inc (EDIT.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... Price To Sales (TTM) 26.58. Price To Book ...Phil Nadeau’s Buy rating for Editas Medicine’s stock is premised on a variety of factors. Key among these is the company’s strong financial position, with reported cash reserves of $446 ...The stock price of Editas Medicine (NASDAQ: EDIT), a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one ...Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy ...Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsComplete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.Check out our EDIT stock analysis, current EDIT quote, charts, and historical prices for Editas Medicine stock

Jun 28, 2023 · Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... Dec 1, 2023 · Summary of all time highs, changes and price drops for Editas Medicine; Historical stock prices; Current Share Price: US$10.77: 52 Week High: US$11.93: 52 Week Low ... Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Instagram:https://instagram. polstar stockabeonaideanomics stock predictionnasdaq aso View Editas Medicine, Inc EDIT investment & stock information. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. msft azuremargin trading calculator Track Editas Medicine Inc (EDIT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors cf industries inc On June 15, Editas Medicine ( EDIT 3.66%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...Nov 24, 2023 · What is the target price for Editas Medicine (EDIT) stock? A. The latest price target for . Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Tuesday, October 24, 2023. CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …